@Jennifer-Carroll Ah. Thanks for clarifying. I misunderstood that question 466 was in relation to attaching an approved template, and not just for a regular email. Thanks for the quick response!
R
RKpharma
@RKpharma
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
Posts
-
Clarification regarding digitization of APS: Helping healthcare product manufacturers plan for the evolving COVID-19 operational context. -
Clarification regarding digitization of APS: Helping healthcare product manufacturers plan for the evolving COVID-19 operational context.@Jennifer-Carroll Hi Jennifer. Looking at the answer to Question 466, confirming a rep would be allowed in a subject line to have a claim neutral statement ie 'Read about the safety profile of Drug X' and then simply attach a PAAB approved asset with no further verbiage beyond 'as follow up to our conversation'....
-
Clarification regarding digitization of APS: Helping healthcare product manufacturers plan for the evolving COVID-19 operational context.@Jennifer-Carroll Thank you Jennifer for the quick and clarifying response. Super helpful!
-
Clarification regarding digitization of APS: Helping healthcare product manufacturers plan for the evolving COVID-19 operational context.Hi there,
We are aware of the updated guidance with regards to digitization/distribution of PAAB materials as highlighted at the beginning of the COVID restricted environment. As such we have submitted e-mail templates for PAAB approval that should be used for any unsolicited emails where the reps wish to include PAAB approved materials. The question here is with regards to responses to requests, ie. solicited emails as follow up to conversations between the reps and customers, and guidance around what reps are allowed to send to customers.
Thanks,
Rivka